T2 Biosystems (TTOO) Competitors

BIOLASE (NASDAQ:BIOL) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Do analysts rate BIOL or TTOO?

BIOLASE currently has a consensus price target of $1.20, suggesting a potential upside of 0.00%. Given BIOLASE's stronger consensus rating and higher probable upside, analysts clearly believe BIOLASE is more favorable than T2 Biosystems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
T2 Biosystems	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Is BIOL or TTOO more profitable?

BIOLASE has a net margin of -41.65% compared to T2 Biosystems' net margin of -563.16%. T2 Biosystems' return on equity of 0.00% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
T2 Biosystems	-563.16%	N/A	-174.06%

Does the media favor BIOL or TTOO?

In the previous week, T2 Biosystems had 1 more articles in the media than BIOLASE. MarketBeat recorded 1 mentions for T2 Biosystems and 0 mentions for BIOLASE. BIOLASE's average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
T2 Biosystems	Neutral

Do insiders & institutionals hold more shares of BIOL or TTOO?

8.8% of BIOLASE shares are held by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are held by institutional investors. 0.3% of BIOLASE shares are held by company insiders. Comparatively, 0.0% of T2 Biosystems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Which has better valuation and earnings, BIOL or TTOO?

BIOLASE has higher revenue and earnings than T2 Biosystems.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
T2 Biosystems	$7.68M	0.03	-$50.08M	N/A	N/A

Which has more volatility and risk, BIOL or TTOO?

BIOLASE has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.

Summary

BIOLASE beats T2 Biosystems on 9 of the 12 factors compared between the two stocks.